GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » Intrinsic Value: Projected FCF

NUMD (Nu-Med Plus) Intrinsic Value: Projected FCF : $-0.03 (As of Dec. 11, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-12-11), Nu-Med Plus's Intrinsic Value: Projected FCF is $-0.03. The stock price of Nu-Med Plus is $0.0162. Therefore, Nu-Med Plus's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Nu-Med Plus's Intrinsic Value: Projected FCF or its related term are showing as below:

NUMD's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.76
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Nu-Med Plus Intrinsic Value: Projected FCF Historical Data

The historical data trend for Nu-Med Plus's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus Intrinsic Value: Projected FCF Chart

Nu-Med Plus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.04 -0.07 -0.04 -0.04

Nu-Med Plus Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 -0.03 -0.03 -0.03

Competitive Comparison of Nu-Med Plus's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Nu-Med Plus's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nu-Med Plus's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Nu-Med Plus's Price-to-Projected-FCF falls into.



Nu-Med Plus Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Nu-Med Plus's Free Cash Flow(6 year avg) = $-0.25.

Nu-Med Plus's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep24)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-0.2528+-0.205/0.8)/81.348
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nu-Med Plus  (OTCPK:NUMD) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Nu-Med Plus's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0162/-0.032735837186654
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nu-Med Plus Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nu-Med Plus Business Description

Traded in Other Exchanges
N/A
Address
640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.
Executives
William C Hayde director, officer: CEO 76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith 10 percent owner P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl director, officer: VP of Medical Marketing P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen officer: CFO, Sec, Treas, Prin Acct Off 455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait 10 percent owner 514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison director, 10 percent owner, officer: Vice President of Technology 975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon director, 10 percent owner, officer: Vice President of Operations 1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins director, 10 percent owner, officer: CEO 455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111